Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. 21. Mai 2021 Staehler, M., Stöckle, M., Christoph, D. C., Stenzl, A., Potthoff, K., Grimm, M.-O., Klein, D., Harde, J., Brüning, F., Goebell, P. J., Augustin, M., Roos, F., Benz-Rüd, I., Marschner, N., Grünwald, V., 2020 Abstract Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients Metz, M., Semsek, D., Rogmans, G., Hutzschenreuter, U., Fietz, T., Harde, J., Zacharias, S., Hielscher, C., Lorenz, A., Zahn, M.-O., Guth, D., Liebers, S., Berghorn,… Weiterlesen Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study) Zeuschner P., Hölters S., Stöckle M., Seliger B., Mueller A., Bachmann H. S., Grünwald V., Christoph D.C., Stenzl A., Grimm M.-O., Brüning F., Goebell P. Weiterlesen